Evaluating Disparities in Precision Oncology: An Observational Trial in the context of a Real-World Academic Practice Model (EDPO)

B
Bryan Schneider, MD

Primary Investigator

Enrolling By Invitation
18 years and older
All
Phase N/A
10600 participants needed
1 Location

Brief description of study

What is the purpose of this study?
This is a non-randomized observational trial designed to collect detailed clinical, social determinant, and genomic data from patients enrolled in molecular oncology tumor boards across four comprehensive cancer centers.

THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic.

Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:
IU Clinical Trials Office 
Phone: (317) 278-5632

Detailed description of study

What will happen during the study?
  • This study proposes an innovative approach leveraging the molecular tumor boards across four comprehensive cancer centers, where real- world, diverse patients with metastatic cancer are seen receiving a broad scope of therapies in the context of precision medicine. 
  • The study plans to collect detailed clinical, social, and genomic data from patients to identify significant contributors of disparate survival and toxicity outcomes for patients with metastatic cancer.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Metastatic Cancer, Advanced Cancer
  • Age: 18 Years
  • Gender: All

Inclusion Criteria:
  1. Ability to provide written informed consent and HIPAA authorization
  2. Patients must be ≥ 18 years old at the time of consent
  3. Diagnosis of advanced or metastatic cancer and planning to undergo molecular testing as part of their routine cancer care
  4. Patients who self-report race as Black or patients who self-report as White
Exclusion Criteria:
N/A

Updated on 01 Aug 2024. Study ID: CTO-IUSCCC-0819, 19375
Please visit our main page to search for other studies you may be interested in. If you need help finding a study or have any questions, please contact us at inhealth@iu.edu

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center